Prosecution Insights
Last updated: July 17, 2026
Application No. 18/722,637

AQUEOUS LIQUID COSMETIC MATERIAL

Non-Final OA §103§DP
Filed
Jun 21, 2024
Priority
Dec 28, 2021 — JP 2021-214016 +1 more
Examiner
FUBARA, BLESSING M
Art Unit
1613
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
MITSUBISHI PENCIL Company, Limited
OA Round
1 (Non-Final)
62%
Grant Probability
Moderate
1-2
OA Rounds
1y 2m
Est. Remaining
96%
With Interview

Examiner Intelligence

Grants 62% of resolved cases
62%
Career Allowance Rate
795 granted / 1281 resolved
+2.1% vs TC avg
Strong +34% interview lift
Without
With
+34.0%
Interview Lift
resolved cases with interview
Typical timeline
3y 3m
Avg Prosecution
40 currently pending
Career history
1319
Total Applications
across all art units

Statute-Specific Performance

§101
1.0%
-39.0% vs TC avg
§103
47.5%
+7.5% vs TC avg
§102
6.3%
-33.7% vs TC avg
§112
5.5%
-34.5% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1281 resolved cases

Office Action

§103 §DP
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Receipt is acknowledged for preliminary amendment and IDS filed 06/21/2024. Claims 4-8 are amended. Claims 1-8 are pending. Priority This application is a 371 of PCT/JP2022/047719 filed 12/23/2022 which claims benefit of JP application 2021-214016 filed 12/28/2021. Information Disclosure Statement The IDS filed 06/21/2024 has been considered by the examiner. Claim Rejections - 35 USC § 103 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention. Claim(s) 1-8 is/are rejected under 35 U.S.C. 103 as being unpatentable over SUKUMA et al. (WO 2021006289 A1 using US 20220265534 A1 as Eng. Trans of WO 2021006289 A1). The Claimed invention: Claim 1 is an aqueous liquid composition comprising coated and uncoated pigment particles; the coated flaky particles B are the uncoated flaky particles A coated with/surface treated with at least one of crystalline cellulose, dextrin, thickening polysaccharide, emulsion particles containing 4-10 mass% acrylate copolymer; the uncoated particles are the flaky pigment A. Scope and Content of the prior art: SUKUMA discloses aqueous/liquid cosmetic composition comprising 0.01 to 10 mass% flaky pigments coated with 1-20% mass% of an acrylic copolymer and water (see the whole document with emphasis on the abstract, paragraphs [0006], [0019]. [0020]) and the composition is filled in an applicator provided with a brush (paragraphs [0006], [0009], Fig. 1); the preferred amount of the acrylic copolymer is 1-10% (paragraph [0055]). The aqueous/liquid composition comprises thickening agent for inhibiting settling of the flaky pigment (paragraph [0057]) and the thickening agent is at least one of crystalline cellulose, dextrin, xanthan gum, gellan gum, guar gum, cellulose, hydroxycellulose meeting the limitation of thickening polysaccharide (paragraph [0058]). Specific crystalline celluloses, Ceolus RC-591, RC-N81, RC-591NF, CL-611, Ceolus Cream, all manufactured by Asahi Kasei are named (paragraph [0059]). SUKUMA further teaches that the aqueous/liquid composition can contain moisturizer, antimicrobial agent, inorganic pigment and organic pigment, dye, surfactant and water soluble organic solvent (paragraph [0062]). SUKUMA further teaches that the liquid composition comprises blend of organic pigment, AL lake pigment and dye and this blended pigments produce clear color tone in addition to the coated treated flaky pigment (paragraph [0067]). SUKUMA further teaches that Pearl pigment, aluminum flake pigment which is aluminum powder pigment, metal or metal oxide coating glass flake, metal or metal oxide coating glass flake and aluminum-coating polyester film are coated with cellulose hemicellulose, lignin, chitin or chitosan (paragraph [0031]). The flaky pigments in SUKUMA are aluminum flake pigments, metal oxide-coated glass flakes (METASHINE), metal oxide coated mica (LUMINA) (paragraph [0035]). Therefore, SUKUMA’S composition contains coated and uncoated pigments, the uncoated pigments reading of flaky pigment A, and the coated pigments meeting the flaky pigment B. The coated flaky pigment is present at 0.01 to 10% or 0.5 to 8% or 1 to 7% (paragraphs [0034], [0040] and the acrylate copolymer meeting the limitation of emulsion particle is at 1 to10% (paragraph [0055]). The 1 to 10% for the emulsion particles of acrylic based copolymer overlaps the claimed range of 4 to 10%. The 1-7% is a specific point within the claimed range of 1-9%. Differences between the prior art and the claims: For Claim 1,The difference between the prior art and claim 1 is that the amount for the emulsion particles overlaps the claimed range of 4 to 10%. Objective evidence and resolving the level of ordinary skill in the art: It has been established that in the case where the claimed ranges "overlap or lie inside ranges disclosed by the prior art" a prima facie case of obviousness exists. In re Wertheim, 541 F.2d 257, 191 USPQ 90 (CCPA 1976); In re Woodruff, 919 F.2d 1575, 16 USPQ2d 1934 (Fed. Cir. 1990). In the instant case, the range of 1-10% for the emulsion particles allows for a range of 4-10% rendering the claimed range prima facie obvious. Therefore, before the effective date of the invention the artisan guided by the teachings of SUKUMA would use amounts of the emulsion particles, in the case the acrylate, in the liquid cosmetic that would predictably provide clear and brilliant coating film. For claim 2, dextrin meets the limitation. For claim 3, xanthan gum and guar gum meet the limitation. For claim 4, the pH adjuster (see paragraph [0060], [0068], Table 1) meet the limitation. For claim 5, the layered clay material is layered silicate mineral particles (paragraphs [0023], [0043], [0044], claim 4). For claims 6 and 7, the size of the coated pigment is larger than the uncoated pigment (see at least paragraph [0036]), such that the particle size of the untreated/uncoated pigment particle is different from the particle size of the coated pigments. For claim 8, the coated flaky pigment, which is flaky pigment B, is disclosed to have diameter of 5 mm to 100 mm (paragraph [0036]). The diameter of the uncoated pigment is not specifically disclosed. However, the ordinary skilled artisan needing to know how much coating material in terms of the size of the particle, would determine the size of the particle before and after coating to determine the difference between the coated and uncoated particles to predictably determine coating size. Thus, SUKUMA renders claims 1-8 prima facie obvious. Double Patenting The non-statutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A non-statutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969). A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on non-statutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b). The filing of a terminal disclaimer by itself is not a complete reply to a non-statutory double patenting (NSDP) rejection. A complete reply requires that the terminal disclaimer be accompanied by a reply requesting reconsideration of the prior Office action. Even where the NSDP rejection is provisional the reply must be complete. See MPEP § 804, subsection I.B.1. For a reply to a non-final Office action, see 37 CFR 1.111(a). For a reply to final Office action, see 37 CFR 1.113(c). A request for reconsideration while not provided for in 37 CFR 1.113(c) may be filed after final for consideration. See MPEP §§ 706.07(e) and 714.13. The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The actual filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/apply/applying-online/eterminal-disclaimer. Claims 1-5 are rejected on the ground of non-statutory double patenting as being unpatentable over claims 1-4 of U.S. Patent No. 11890363 B2. Although the claims at issue are not identical, they are not patentably distinct from each other because the issued liquid cosmetic composition comprising flaky pigment, surface coated flaky pigment with the coating selected from the group consisting of cellulose, hemicellulose, lignin, chitin and chitosan, layered clay mineral particles, acrylic copolymer; the composition further comprising thickener, the flaky component is aluminum flake pigment, and the layered clay mineral particles are layered silicate mineral particles teaches the claimed liquid cosmetic which is disposed in an applicator equipped with a brush. No claim is allowed. The lengthy specification has not been checked to the extent necessary to determine the presence of all possible minor errors. Applicant’s cooperation is requested in correcting any errors of which applicant may become aware in the specification. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to BLESSING M FUBARA whose telephone number is (571)272-0594. The examiner can normally be reached 7:30 am-6 pm (M-T). Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Brian Yong Kwon can be reached at 5712720581. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /BLESSING M FUBARA/Primary Examiner, Art Unit 1613
Read full office action

Prosecution Timeline

Jun 21, 2024
Application Filed
Jun 25, 2026
Non-Final Rejection mailed — §103, §DP (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12673051
COMPOSITION AND PRODUCT THEREOF
3y 9m to grant Granted Jul 07, 2026
Patent 12672868
Sutures with Expanded Antibacterial Properties
3y 2m to grant Granted Jul 07, 2026
Patent 12649669
METHOD FOR MICROORGANISM GROWTH INHIBITION
2y 5m to grant Granted Jun 09, 2026
Patent 12642882
DRUG DELIVERY SYSTEM AND METHODS OF USING THE SAME
3y 5m to grant Granted Jun 02, 2026
Patent 12635719
DELAYED RELEASE SOFTGEL CAPSULES IN HIGHER PH ENVIRONMENT
1y 9m to grant Granted May 26, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
62%
Grant Probability
96%
With Interview (+34.0%)
3y 3m (~1y 2m remaining)
Median Time to Grant
Low
PTA Risk
Based on 1281 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month